{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-061441","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.590365+00:00","generated_at":"2026-05-23T00:19:04.502950+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alkermes Q1 2025 revenue $306.5M, GAAP EPS $0.13; reaffirms 2025 guidance","bullets":["Total revenues $306.5M, down from $350.4M in Q1 2024; GAAP net income $22.5M ($0.13 diluted EPS).","Proprietary net sales $244.5M (+5% YoY); LYBALVI grew 23% to $70.0M, VIVITROL $101.0M, ARISTADA $73.5M.","Cash and investments $916.2M, up from $824.8M at Dec. 31, 2024.","ALKS 2680 phase 2 Vibrance-1 enrollment complete; topline data expected early Q3 2025.","Company reiterates full-year 2025 financial expectations as communicated Feb. 12, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-061441","json":"https://secwatch.observer/filing/0000950170-25-061441.json","markdown":"https://secwatch.observer/filing/0000950170-25-061441.md","text":"https://secwatch.observer/filing/0000950170-25-061441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017025061441/0000950170-25-061441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017025061441/alks-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:19:04.502950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}